生物谷报道:一类包括吉非替尼(gefitinib,商品名易瑞沙Iressa)和埃洛替尼(erlotinib,商品名Tarceva)的新“智能”抗癌药物被用来治疗肺癌,该类药物抑制癌细胞的生长。然而,几乎是不可避免的,这些肿瘤对药物产生了抗药性,又开始重新生长。Jeff Engelman和一个国际小组研究了针对gefitinib的抗药性,发现一组癌症复发的患者中,一个与以前相同的细胞信号发生通道被激活,但通过的是一个的名为MET的不同基因的扩增。这项研究也许与某些胃、头颈癌也有关。该研究结果发表在4月27日的《科学》快递上。
原文出处:
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Jeffrey A. Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi, Youngchul Song, Courtney Hyland, Joon Oh Park, Neal Lindeman, Christopher-Michael Gale, Xiaojun Zhao, James Christensen, Takayuki Kosaka, Alison J. Holmes, Andrew M. Rogers, Federico Cappuzzo, Tony Mok, Charles Lee, Bruce E. Johnson, Lewis C. Cantley, and Pasi A. Jänne
Published online 26 April 2007 [DOI: 10.1126/science.1141478] (in Science Express Reports)
Abstract » PDF » Supporting Online Material »
相关基因:
MET
Official Symbol: MET and Name: met proto-oncogene (hepatocyte growth factor receptor) [Homo sapiens]
Other Aliases: HGFR, RCCP2
Other Designations: Oncogene MET; met proto-oncogene
Location: 7q31
Chromosome: 7 Annotation: NC_000007.12 (116099694..116225675)
MIM: 164860
GeneID: 4233